CION Ameerpet
The RMI multiplies three things into a single number, and it is a sorting tool rather than a diagnosis. Its job is deciding which service should look after you — not telling you what you have.
Ovarian cancer outcomes are measurably better when staging and debulking surgery are performed by a specialist gynaecologic-oncology surgeon. That creates a practical problem: ovarian masses are common, specialist centres are not, and sending every woman with a cyst to a cancer centre would be neither possible nor kind.
The Risk of Malignancy Index exists to solve exactly that. It takes three things that are already available — the ultrasound findings, whether you have been through the menopause, and your CA-125 — and combines them into a single number that sorts women into a low-risk group and a high-risk group.
Low-risk masses are managed by general gynaecology, which is appropriate and safe for the great majority. High-risk masses go to a specialist service, where the surgeon and the team have the experience that improves outcomes. That is the whole purpose. The RMI is a signpost, not a diagnosis — and reading it as a probability that you have cancer is the single commonest misunderstanding about it.
Which creates a sorting problem: masses are common, specialist centres are not.
Ultrasound findings, menopausal status and CA-125 — all already obtained during assessment.
Low risk stays local; high risk goes to a specialist service. It is a signpost, not a diagnosis.
The RMI works by multiplication, not addition, and that has a consequence worth understanding. Because the ultrasound score, the menopausal factor and the CA-125 are multiplied together, a single high input can dominate the result. A post-menopausal woman with a substantially raised CA-125 can cross the referral threshold even with fairly modest ultrasound findings — and a premenopausal woman with concerning imaging can score below it if her CA-125 happens to be normal. This is precisely why the score is a triage instrument and never the final word: a clinician who is worried about a scan should act on that worry regardless of the number. Source: published RMI methodology and validation studies.
RMI = U x M x CA-125. Different versions of the index score the components slightly differently, so exact numbers vary by centre.
| Component | What it measures | How it is scored |
|---|---|---|
| U — ultrasound score | Multilocular cyst, solid areas, bilateral disease, ascites, intra-abdominal metastases. | A point for each feature present, converted to a score. More features means a higher U. |
| M — menopausal status | Whether you have been through the menopause. | A low value if premenopausal, a substantially higher one if post-menopausal. |
| CA-125 | The serum marker value in U/mL. | Entered directly, so a very high value strongly influences the result. |
| The product | All three multiplied together. | Compared against a threshold — commonly around 200 — to sort low from high risk. |
*Because the components are multiplied, one very high value can carry the score across the threshold on its own. Several versions of the RMI exist with different scoring conventions, so your centre's threshold may differ.
The score has one job. Understanding what it does and does not claim makes it far less frightening.
This is the point that gets lost most often. A score above the threshold places you in a group where specialist assessment is warranted — it does not state a probability that you personally have cancer. A substantial proportion of women referred on a high RMI turn out to have entirely benign disease.
Being referred to a gynaecologic-oncology service is the system working as designed. It means any mass that cannot be confidently characterised is assessed by the team with most experience of characterising them, which is better for you whichever way it turns out.
A score below the threshold supports local management, and for the great majority of women that is entirely appropriate. But the index has false negatives, and there are recognised situations where it under-performs.
The most important is mucinous ovarian cancer, which frequently produces little CA-125 even when disease is present — so the CA-125 input, and therefore the whole product, can be misleadingly low. A concerning scan with a low RMI should still be taken seriously.
The menopausal factor is deliberately lower before the menopause, and this reflects reality: ovarian cancer is less common in younger women, and the benign conditions that raise CA-125 — endometriosis, fibroids, pelvic infection, menstruation — are far more common.
The consequence is that RMI performs less well in premenopausal women, where CA-125 is a noisier input. This is one reason some services use ROMA, which incorporates HE4 and is less affected by those benign conditions. See HE4 and ROMA.
The U score counts specific features: a multilocular cyst, solid areas within the mass, disease in both ovaries, ascites, and evidence of spread within the abdomen. Each contributes, and more features means a higher score.
These are the same features that matter on any scan report, and it is worth knowing which of them your scan showed rather than only the final number. See reading a scan report.
RMI is designed and validated for women who already have a known adnexal mass. It is not a screening tool and calculating it in a woman with normal ovaries produces a result that cannot be interpreted meaningfully.
It also does not apply well in pregnancy, where CA-125 rises physiologically and the test becomes essentially uninterpretable. And it is not designed for women under 40 with suspected germ cell tumours, where different markers are relevant. See germ cell markers.
Both are triage instruments doing the same job, and neither is clearly superior in every situation. RMI incorporates the ultrasound findings directly, which is a real advantage. ROMA incorporates HE4, which is less confounded by benign gynaecological disease, which is a different advantage.
Which is used depends largely on local practice and whether HE4 testing is available. If your assessment used one rather than the other, that is standard practice rather than a lesser work-up.
These turn a number into something interpretable.
Thresholds vary between centres and versions of the index. The number alone means little without the cut-off used.
Solid areas, bilateral disease, ascites — knowing which contributed tells you more than the total does.
It is a multiplier, so a misclassification changes the result substantially.
These often produce little CA-125, which can make the score misleadingly low despite a concerning scan.
It should lead to a specific action — local management, referral, or further imaging. Ask which.
Where the mass is indeterminate, MRI often resolves it into a confident benign diagnosis and avoids surgery.
If your clinician is worried about the scan but the score is low, the worry should win. The RMI is a triage aid, not an override on clinical judgement.
Being sent to a specialist service means the score did its job. A substantial proportion of women referred that way turn out to have entirely benign disease.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Bring the scan report and CA-125 — the score is only interpretable with both.
Scores land badly because they look definitive. A single number with a category attached reads like a verdict, when what it actually determines is which clinic manages you. Women referred on a high RMI frequently arrive believing they have been told they have cancer, which is not what the score says at all.
Your first consultation at CION is free and runs to about 45 minutes. Bring the scan report and the CA-125 value alongside the score, because the score is close to uninterpretable without them. Often the more useful conversation is about what the ultrasound showed independently — which specific features were present, and what they suggest on their own terms.
Where the assessment does warrant specialist care, every case that raises a question is reviewed at a tumour board rather than decided by one clinician. Chemotherapy and maintenance therapy are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, alongside genetic counselling and BRCA and HRD testing. Staging and debulking surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there.
Free and unhurried. Long enough to explain what a triage score does and does not claim.
The score is close to uninterpretable without the inputs that produced it.
A high score sends you to the team best placed to characterise the mass. Many turn out benign.
Staging and debulking performed at specialist gynaecologic-oncology partner centres and may be billed there.
It is worth stepping back from scores entirely. For characterising an ovarian mass, ultrasound in trained hands remains the most informative single assessment — more so than CA-125, and more so than any index built from it.
Standardised systems based purely on ultrasound features classify the large majority of adnexal masses confidently as benign or concerning, leaving only a minority genuinely indeterminate. Scores like RMI earn their place mainly in triage — routing women to the right service — rather than in telling anyone what they have.
The practical implication: if your scan described a simple cyst with clear fluid, thin walls, one compartment and no internal blood flow, that is a strongly reassuring finding whatever the arithmetic produces. And a solid mass with internal Doppler flow warrants full assessment even where the score sits below the threshold. The score modifies the picture; the imaging draws it.
In trained hands it characterises most masses confidently — more informative than any marker or index.
Their job is routing women to the right service, not telling any individual what she has.
A simple cyst with no solid areas or flow is a strong finding whatever the score.
Solid areas with Doppler flow warrant assessment even with a below-threshold score.
It is a triage score used to decide whether a woman with an ovarian mass should be managed by general gynaecology or referred to a specialist gynaecologic-oncology service. It multiplies three things together: an ultrasound score based on specific features, a factor reflecting whether you have been through the menopause, and your CA-125 value. The product is compared against a threshold — commonly around 200, though this varies by centre and by which version of the index is used — to sort masses into low-risk and high-risk groups. Its purpose is routing, not diagnosis.
No, and this is the commonest misunderstanding about it. A score above the threshold places you in a group where specialist assessment is warranted — it does not state a probability that you personally have cancer, and a substantial proportion of women referred on a high RMI turn out to have entirely benign disease. Being sent to a gynaecologic-oncology service means the score did its job: any mass that cannot be confidently characterised gets assessed by the team with the most experience of characterising them, which is better for you whichever way it turns out.
Yes, in both directions, which is why it is a triage aid rather than a diagnostic test. False positives are common — many women above the threshold have benign disease. False negatives matter more: mucinous ovarian cancers frequently produce little CA-125 even when disease is present, so that input, and therefore the whole multiplied product, can be misleadingly low. Because the components are multiplied, a single value also carries disproportionate weight. If your clinician is worried about the scan but the score is low, that clinical worry should take precedence.
Because the index multiplies rather than adds, so one high input can dominate the result. A substantially raised CA-125 in a post-menopausal woman — where the menopausal multiplier is also high — can carry the product across the threshold even with relatively modest ultrasound findings. The reverse happens too. It is worth asking which specific ultrasound features were counted and what your CA-125 was, because knowing which component drove the score tells you considerably more than the total. And remember that many benign conditions raise CA-125.
Neither is clearly superior in every situation, and both do the same job. RMI incorporates the ultrasound findings directly, which is a genuine advantage since imaging is the most informative element. ROMA incorporates HE4, a marker much less affected by endometriosis, fibroids and other benign gynaecological conditions, which is an advantage particularly in premenopausal women where CA-125 is a noisy input. Which is used depends largely on local practice and whether HE4 testing is available. If your assessment used one rather than the other, that is standard rather than a lesser work-up.
No. It is designed and validated specifically for women who already have a known adnexal mass, and calculating it in a woman with normal ovaries produces a result that cannot be interpreted meaningfully. It also does not apply well in pregnancy, where CA-125 rises physiologically and becomes essentially uninterpretable, and it is not designed for younger women with suspected germ cell tumours, where entirely different markers are relevant. Using it outside its intended context produces the same problem as any misapplied test: alarm without information.
The first consultation is free and runs to about 45 minutes — bring the scan report and the CA-125 value alongside the score, since the score is close to uninterpretable without them. Often the more useful conversation is about what the ultrasound showed independently, which specific features were present and what they suggest on their own terms. Every case that raises a question is reviewed at a tumour board. Chemotherapy, maintenance therapy, genetic counselling and BRCA and HRD testing are delivered in-house across more than 35 centres; surgery is coordinated with specialist partner centres and may be billed there.